,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['breast', 'enhertu', 'astrazeneca']
astrazeneca and daiichi set a new standard in her2-negative breast cancer with enhertu data at #asco22, broadening poc for adcs 
The leading voice for decision-makers throughout the global biopharma ecosystem. 
Free weekly podcast "BioCentury This Week": https://t.co/6CfHh0mIT6